• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Evidence That Increasing Serum 25(OH)D Concentrations to 30 ng/mL in the Kingdom of Saudi Arabia and the United Arab Emirates Could Greatly Improve Health Outcomes
Biomedicines. 2023 Mar 23;11(4):994. doi: 10.3390/biomedicines11040994.ABSTRACTAccumulating evidence supports the potential protective effects of vitamin D against chronic diseases such as Alzheimer's disease, autoimmune diseases, cancers, cardiovascular disease (ischaemic heart disease and stroke), type 2 diabetes, hypertension, chronic kidney disease, stroke, and infectious diseases such as acute respiratory tract diseases, COVID-19, influenza, and pneumonia, as well as adverse pregnancy outcomes. The respective evidence is based on ecological and observational studies, randomized controlled trials, mechanistic studies, ...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: William B Grant Fatme Al Anouti Barbara J Boucher Hana M A Fakhoury Meis Moukayed Stefan Pilz Nasser M Al-Daghri Source Type: research

An Evidence-Based Review of Vitamin D for Common and High-Mortality Conditions
Conclusion: Prospective studies of vitamin D supplementation demonstrate variable impact on disease specific and patient-oriented outcomes, suggesting a correlation but not a causal relationship between low vitamin D levels and disease pathogenicity. Future research should determine dosing standards and timing of vitamin D in treatment and prevention.
Source: Journal of the American Board of Family Medicine - December 23, 2022 Category: Primary Care Authors: Michael, W., Couture, A. D., Swedlund, M., Hampton, A., Eglash, A., Schrager, S. Tags: Clinical Review Source Type: research

COVID-19-Associated Coagulopathy: Role of Vitamins D and K
Curr Pharm Biotechnol. 2022 May 27. doi: 10.2174/1389201023666220527110455. Online ahead of print.ABSTRACTRecent reports show coagulopathy as a potential complication and poorer outcome of coronavirus disease 2019 (COVID-19), especially in those with comorbid conditions such as diabetes and hypertension as thrombosis could result in stroke and heart attacks. Indeed, cardiovascular complications in COVID-19 accounts for 40% of mortality. Although there is no standard treatment protocol or guidelines for COVID-19, it is a common practice to use anti-inflammatory corticosteroids and anti-coagulants, especially for severe COVI...
Source: Current Pharmaceutical Biotechnology - May 31, 2022 Category: Biotechnology Authors: Bruk Getachew Harold E Landis Kebreten F Menaye Yousef Tizabi Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.PMID:33898022 | PMC:PMC8053362 | DOI:10.1016/j.amsu.2021.102309
Source: Annals of Medicine - April 26, 2021 Category: Internal Medicine Authors: Abdelilah El Rhalete Inas Rhazi Amine Bensaid Ikram Zaid Houssam Bkiyer Nabila Ismaili Nouha Elouafi Brahim Housni Source Type: research